urology
D'Amico Risk Stratification for Localised Prostate Cancer
Stratifies localised prostate cancer recurrence risk after definitive treatment (D'Amico 1998). Combines PSA, Gleason and clinical T-stage. Underpins NICE NG131 treatment recommendations.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Gleason Score / Grade Group for Prostate Cancer · Prostate Cancer
- Prostate Cancer Risk Stratification (NICE / EAU) · Prostate Cancer
- UCSF-CAPRA Score for Prostate Cancer · Prostate Cancer
- PSA Doubling Time (PSADT) Calculator · Prostate Cancer
- D'Amico Risk Classification for Prostate Cancer · Prostate Cancer
- PSA Velocity and PSA Density · Prostate Cancer
Drugs
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.